Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

[Sexuality of men with neurologic disorders].
Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases.
UCSF Neuroimmunology Research Seminar
A new prevalence study of multiple sclerosis in Orkney, Shetland and Aberdeen city.
Demyelinating Diseases: Myeloperoxidase as an Imaging Biomarker and Therapeutic Target.
Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab.
Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis.
The genetics of multiple sclerosis.
Treatment of HIV and Risk of Multiple Sclerosis.
Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses.
Uncovering Cryptic Glycan Markers in Multiple Sclerosis (MS) and Experimental Autoimmune Encephalomyelitis (EAE).
[Cognitive performance and quality of life in multiple sclerosis in Gipuzkoa].
Effects of sleep and wake on oligodendrocytes and their precursors.
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
A new cognitive rehabilitation programme for patients with multiple sclerosis: the 'MS-line! Project'
The Ambivalent Role of Apoptosis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
Non-lesional white matter changes in pediatric multiple sclerosis and monophasic demyelinating disorders.
Very early MS -- insights from MRI.
Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.
Can we safely target the WNT pathway?
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
The autonomic balance predicts cardiac responses after the first dose of fingolimod.
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.
High-dose cyclophosphamide in the treatment of multiple sclerosis.

Pages